A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.
For details about CAPS-UK, and the conditions you agree to be bound by, please see our Terms and Conditions.
This page brought to you by USEQ\WEB21.
Recs
Top line Positive phase 3 drug report from Japan, and 100million license fee, you know this company is not going down any time soon!